The Combined Impact of Surgery and Immunomodulation With Low Dose Cytoxan and GM-CSF in the Early Treatment of Breast Cancer
Abstract
The purpose of this study was to evaluate the combined impact of surgery and immunomodulation with low dose cytoxan and GM-CSF on the development of dendritic cells and the activation of T cells in vivo. MMTV Her2/neu mice, which spontaneously develop mammary tumors were treated with combinations of cytoxan, GM-CSF and surgery. Flow cytometry was used to evaluate blood (B), lymph nodal tissue (LN), and splenocytes (S) for evidence of monocyte differentiation to dendritic cells (DC). Both tumor naive mice and mice with spontaneous tumor growth were evaluated. With this study we were able to identify a subpopulation of monocytic cells with characteristics consistent with partial differentiation to dendritic cells using the cell surface markers CD11C, MHC II, CD86/CD40, CD80, and Ly6c. While this study was unable to demonstrate alteration of the cell surface markers of the monocytic cell populations in a manner consistent with dendritic cell differentiation using GM-CSF or cytoxan, this study suggests that the presence of tumor itself may alter the CD40 and MHC II level in the spleen and that the presence of tumor itself may lead to early differentiation of the dendritic cell population in the spleen.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2004
- Accession Number
- ADA432547
Entities
People
- Kari L. Kendra
Organizations
- Ohio State University